Alliance Foundation Trials, LLC (AFT)

Alliance Foundation Trials, LLC (AFT) is a research organization that develops and conducts cancer clinical trials, working closely with the Alliance for Clinical Trials in Oncology scientific investigators and institutional member network, research collaborators, and non-NCI funding sources. AFT seeks to fulfill the vision of the Alliance for Clinical Trials in Oncology to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines committed to discovering, validating, and disseminating effective strategies for the prevention and treatment of cancer. Established in 2014 as a limited liability corporation, AFT is the sole member of the Alliance for Clinical Trials in Oncology Foundation. Current AFT studies are funded by a number of pharmaceutical company collaborators and the Patient-Centered Outcomes Research Institute (PCORI). For more information about developing an AFT study, visit

** Participation in AFT is restricted to Alliance members in good standing that fulfill the specific study feasibility criteria.**

Active AFT Trials
Select from the links below to learn more about specific AFT trials that are currently recruiting participants. 

AFT-05 | Breast Cancer
Palbociclib collaborative adjuvant study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive/HER2-negative breast cancer
AFT PI: Erica Mayer, MD
Phase: Phase III
Opened: 08/26/2015

A phase 1 dose escalation and phase 2 randomized, placebo-controlled study of the efficacy and tolerability of veliparib in combination with paclitaxel/carboplatin-based chemoradiotherapy followed by veliparib and paclitaxel/carboplatin consolidation in subjects with stage III non-small cell lung cancer (NSCLC)
AFT PI: J. Salama and T. Stinchcombe
Phase: Phase I/II
Opened: 8/4/16

A phase I, open-label, multi-center trial of oral azacitidine (CC-486) plus R-CHOP in subjects with high risk (IPI 3 or more) previously
untreated diffuse large B-cell lymphoma or grade 3B follicular lymphoma

AFT PI: P. Martin
Phase: Phase I
Opened: 2/28/17

AFT-09/Pembrolizumab | Lung Cancer
A randomized phase II trial evaluating the optimal sequencing of PD-1 inhibition with pembrolizumab (MK-3475) and standard platinum-based chemotherapy in patients with chemotherapy naive stage IV non-small cell lung cancer
AFT PI: Thomas Hensing, MD
Phase: Phase II
Opened: 03/1/16

AFT-16 | Lung Cancer
Phase II trial of induction immunotherapy with anti-PD-L1 for PD-L1 positive patients with unresectable stage IIIA and IIIB
NSCLC eligible for chemoradiotherapy with curative intent

AFT PI: Helen J. Ross, MD
Phase: Phase II
Opened: 11/1/17

AFT-19/PRESTO | Prostate Cancer
A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer
AFT PI: Rahul Aggarwal, MD
Phase: Phase III
Opened: 2/28/17

AFT-25 | Ductal Carcinoma in Situ (DCIS)
Comparison of operative to monitoring and endocrine therapy (COMET) trial for low risk DCIS: A phase III prospective randomized trial
AFT PI: E. Shelley Hwang MD, MPH
Phase: Phase III prospective randomized trial
Opened: 2/22/17

A study comparing atezolizumab (anti PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer (IMpassion030)
AFT PI: H. McArthur
Phase: Phase III
Opened: 5/1/18

AFT-28 | Randomized Effectiveness
The benefits, harms and burdens of DOAC versus LMWH +/- warfarin for venous blood clots in cancer: A pragmatic randomized trial (CANVAS trial)
AFT PIDeborah Schrag, MD and Jean Connors, MD
Phase: N/A
Opened: 11/7/16

Phase 2, randomized, open-label study comparing daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) versus
lenalidomide, bortezomib, and dexamethasone (RVd) in subjects with newly diagnosed multiple myeloma eligible for high-dose
chemotherapy and autologous stem cell transplantation

AFT PI: P. Voorhees
Phase: Phase II
Opened: 8/29/16

AFT-32 | Mantle Cell Lymphoma
A phase II study of palbociclib in combination with ibrutinib in patients with previously treated mantle cell lymphoma
AFT PI: Kami Maddocks, MD
Phase: Phase II
Opened: 9/6/18

AFT-38 | Breast Cancer
A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer
AFT PI: Otto Metzer, MD
Phase: Phase III
Opened: 7/11/17

Electronic patient reporting of symptoms during cancer treatment (PRO-TECT) - (randomized effectiveness trial)
AFT PI: E. Basch
Phase: N/A
Opened: 10/4/17

Pending Activation

AFT-15 | Multiple Myeloma
A phase I/II study of ibrutinib (PCI-32765) in combination with revlimid/dexamethasone (Rd) in relapsed/refractory multiple myeloma
AFT PI: Yvonne A Efebera, MD MPH and Jacob P. Laubach, MD
Phase: Phase I/II

AFT-41 | Multiple Myeloma
A phase II study of lenalidomide, ixazomib, dexamethasone, and daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma
AFT PI: Elizabeth K. O’Donnell, MD
Phase: Phase II

AFT-42 | Lung Cancer/ Autoimmune
Safety, activity and pharmacology of nivolumab in patients with advanced non-small cell lung cancer and pre-existing autoimmune disease
AFT PI: Rebecca S. Heist, MD MPH
Phase: Phase I/II

AFT-46 | Lung Cancer
CHIO3 Trial: Chemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B non-small cell lung cancer
AFT PI: L. Martin, MD and J. Patel, MD
Phase: Phase III

AFT-47 |
ARACOG: Phase II study of androgen receptor and cognitive function in patients treated with darolutamide or enzalutamide
AFT PI: C. Ryan, MD and A. Morgans, MD
Phase: Phase II

ICARE data |
Integrating clinical trials and real-world endpoints, in collaboration with the MITRE Corporation
AFT PI: M. Fairweather, MD
Phase: N/A

AFT Trials In Development

AFT-35 | Multiple Myeloma
Phase I/II multicenter, open-label, dose-escalation study of the combination of pomalidomide, bortezomib, low-dose dexamethasone, and daratumumab, in patients with relapsed or refractory multiple myeloma
AFT PI: Hani Hassoun, MD
Phase: Phase I/II

AFT-49 | Multiple Myeloma
Randomized trial of consolidation targeted adjuvant therapy with encorafenib, binimetinib, and cetuximab versus usual care for patients with stage III V600E colon cancer
AFT PI: R. Yaeger, MD
Phase: Phase III